Salivary Gland Neoplasms × pembrolizumab × Clear all
NCT03556228 2025-12-11

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

VM Oncology, LLC

Phase 1/2 Recruiting
242 enrolled
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 9 FDA
NCT04140526 2025-05-23

PRESERVE-001

OncoC4, Inc.

Phase 1/2 Active not recruiting
733 enrolled